What this story covers

Viatris's 2023 10-K reveals 15 point 43 billion dollars revenues down 5 percent due to divestitures and forex, with net earnings at 54 point 7 million dollars. Key moves include OTC sale for 2 point 17 billion dollars, Oyster Point acquisition boosting Tyrvaya sales to 41 point 7 million dollars. Strategy shifts to complex products in ophthalmology; strong liquidity supports debt reduction amid risks like competition and regulations.

Story snapshot